CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders

J Immunol. 2020 Jan 1;204(1):3-11. doi: 10.4049/jimmunol.1900868.

Abstract

CD13/aminopeptidase N is a widely expressed ectoenzyme with multiple functions. As an enzyme, CD13 regulates activities of numerous cytokines by cleaving their N-terminals and is involved in Ag processing by trimming the peptides bound to MHC class II. Independent of its enzymatic activity, cell membrane CD13 functions by cross-linking-induced signal transduction, regulation of receptor recycling, enhancement of FcγR-mediated phagocytosis, and acting as a receptor for cytokines. Moreover, soluble CD13 has multiple proinflammatory roles mediated by binding to G-protein-coupled receptors. CD13 not only modulates development and activities of immune-related cells, but also regulates functions of inflammatory mediators. Therefore, CD13 is important in the pathogenesis of various inflammatory disorders. Inhibitors of CD13 have shown impressive anti-inflammatory effects, but none of them has yet been used for clinical therapy of human inflammatory diseases. We reevaluate CD13's regulatory role in inflammation and suggest that CD13 could be a potential therapeutic target for inflammatory disorders.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Antigen Presentation / immunology
  • CD13 Antigens / antagonists & inhibitors*
  • CD13 Antigens / metabolism*
  • Cytokines / metabolism
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / pathology*
  • Phagocytosis / immunology
  • Receptors, Cytokine / metabolism
  • Signal Transduction / immunology

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Receptors, Cytokine
  • CD13 Antigens